{"id":"W4399218247","doi":"10.1200/jco.24.00581","title":"Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Grifols; Lunit; Sociedad Española de Oncología Médica; BeiGene; Taiho Pharmaceutical; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; ALK inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001989972,0.0005087357,0.001515062,0.0002145894,0.00021111,0.0006361206,0.0003614844,0.0003806302,0.0008965219],"category_scores_gemma":[0.001523509,0.0002099752,0.001609653,0.0002694825,0.0004589282,0.0003890356,0.0003027693,0.001138446,0.0001387468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001027147,"about_ca_system_score_gemma":0.0009037572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001875407,"about_ca_topic_score_gemma":0.006183122,"domain_scores_codex":[0.9993141,0.0003679492,0.00005398683,0.00009068822,0.00009167929,0.00008156621],"domain_scores_gemma":[0.9987957,0.000276816,0.0004581215,0.00007682361,0.00007938798,0.0003130354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8672153,0.002552809,0.05505187,0.0006662023,0.004671429,0.00009726262,0.00013886,0.002344534,0.007349099,0.0001101364,0.001916073,0.05788636],"study_design_scores_gemma":[0.409042,0.296106,0.2716739,0.0001229738,0.007307458,0.0004605564,0.0002117,0.00571278,0.003680754,0.0003590982,0.005232817,0.00008982456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952149,0.003551104,0.000100819,0.0001313095,0.00003163496,0.0001478412,0.0003088389,0.00001018596,0.0005033101],"genre_scores_gemma":[0.9973587,0.0009932803,0.0002726373,0.0002005656,0.000083829,0.0001035971,0.0007181659,0.000003357307,0.0002658968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001989972,"threshold_uncertainty_score":0.01052409,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04732648856136055,"score_gpt":0.475723419983027,"score_spread":0.4283969314216664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}